A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Cancer Non Hodgkin Lymphoma (NHL) Follicular Lymphoma Diffuse Large B-Cell Lymphoma (DLBCL)
For the latest version of this information please go to www.forpatients.roche.com